United States Infection Control Market Size, Share, Latest Insights and Forecast 2025-2033

IMARC Group has recently released a new research study titled "United States Infection Control Market Size, Share, Trends and Forecast by Type, End User, and Region, 2025-2033" which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

Market Overview

The United States infection control market was valued at USD 12.75 Billion in 2024 and is expected to reach USD 22.25 Billion by 2033, expanding at a CAGR of 6.29% during the forecast period 2025-2033. Growth is driven by rising hospital-acquired infections (HAIs), strict regulatory standards, and advances in sterilization technologies. Demand is bolstered by increasing healthcare investments, the usage of single-use medical products, and rising adoption of automated disinfection solutions across healthcare, laboratory, and pharmaceutical sectors.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

United States Infection Control Market Key Takeaways

• Current Market Size: USD 12.75 Billion in 2024
• CAGR: 6.29% (2025-2033)
• Forecast Period: 2025-2033
• The market growth is supported by stringent sterilization and disinfection standards enforced by CDC, FDA, and private entities.
• Technological advancements such as UV disinfection, hydrogen peroxide vapor sterilization, and antimicrobial coatings are shaping infection control.
• Increasing outsourcing of infection control services by healthcare facilities supports operational efficiency and cost savings.
• Demand for personal protective equipment (PPE) remains strong due to ongoing infection control policies and growing home healthcare services.
• The rise of multidrug-resistant organisms (MDROs) is driving more rigorous infection prevention efforts.
• Government initiatives to improve sanitation systems in public healthcare are further propelling market expansion.

Sample Request Link: https://www.imarcgroup.com/united-states-infection-control-market/requestsample

United States Infection Control Market Growth Factors:

In the US, the infection control market is growing as HAIs become more popular and as government and regulatory policies change to prevent their occurrence (for example, in October 2023, the CDC published draft recommendations for the use of NIOSH-approved respirators and eye protection to prevent pathogen transmission in healthcare settings). This demand is exacerbated by stringent mandates and regulations. Hospitals performing a greater number of surgeries are especially likely to make use of infection control technology to reduce risk. Other factors influencing hospital demand include an aging population and increasing hospitalization incidences from chronic diseases.

New developments in infection control include sterilization/disinfection techniques such as ultraviolet C systems, hydrogen peroxide vapor, ethylene oxide (EtO), plasma sterilization, and antimicrobial bed and surface coating for hospital use in hospitals. About 20 billion sterile medical devices are made each year in the United States using ethylene oxide for around half of them. In January 2024, the FDA also formally recognized vaporized hydrogen peroxide sterilization as a consensus method and encouraged facilities to adopt alternative technologies that would reduce EtO supply chain risk, decrease emissions, improve productivity, and help combat antimicrobial resistance.

Healthcare facilities show a growing trend to outsource infection control services to third-party vendors. In some cases, central sterile processing departments (CSPDs) outsourced to specialized contractors can with complex sterilization regulations and compliance monitoring help generate savings and efficiency particularly. The Cameron Memorial Community Hospital saved USD 38000 in laundry costs after outsourcing laundry to another company, following protocol for infection control, allowing more focus on patient care, and keeping a constant demand for PPE equipment including gloves, masks, and gowns. To address shortages of PPE, USD 350 million was invested by six US companies to make medical gowns for the Planned National Stockpile in October 2024. New PPE with antimicrobial fabrics and reusable high-filtration masks are supplementing existing hospital, laboratory, and home health infection control.

Buy Report Now: https://www.imarcgroup.com/checkout?id=20447&method=1190

United States Infection Control Market Segmentation:

Breakup by Type:

• Equipment
• Services
• Consumables
• Others

Breakup by End User:

• Hospitals and Clinics
• Medical Device Companies
• Clinical Laboratories
• Pharmaceutical Companies
• Others

Segment Descriptions:

• Equipment: Includes sterilizers, disinfection systems, air filtration units, and UV-C disinfection devices essential for sterile environments in hospitals, labs, and pharmaceutical facilities. Devices like autoclaves, vaporized hydrogen peroxide sterilizers, and ultrasonic cleaners eliminate pathogens from instruments and surfaces. Growth is driven by regulatory requirements, HAI prevention, and increasing surgeries.

• Services: Covers decontamination, sterilization validation, on-site equipment maintenance, and waste management. Healthcare, medical device, and pharmaceutical companies depend on professional consulting and outsourced sterilization to comply with FDA, CDC, and Joint Commission mandates. Increasing use of contract sterilization for single-use medical devices and biopharmaceuticals promotes market expansion.

• Consumables: Comprises disinfectants, sterilization wraps, gloves, masks, gowns, and single-use supplies imperative for preventing cross-contamination. Hospitals and labs regularly replenish these to comply with infection prevention protocols. Demand for alcohol-based sanitizers and antimicrobial coatings rises with infection risk.

• Hospitals and Clinics: Major end users requiring stringent sterilization protocols, disinfection systems, and PPE to curb HAIs. Regulatory bodies enforce strict infection prevention, driving continuous investment in advanced solutions.

• Medical Device Companies: Rely on strict sterilization and contamination control for product safety and compliance, using EtO, gamma radiation, and hydrogen peroxide vapor methods for devices like implants and catheters. Rising single-use device adoption fuels demand.

• Clinical Laboratories: Require infection control to maintain biosafety and prevent cross-contamination in diagnostics. Solutions include biosafety cabinets, automated sterilization, and high-level disinfectants, complying with FDA and CDC biosafety level guidelines.

• Pharmaceutical Companies: Employ contamination control with cleanroom sterilization, air filtration, and chemical disinfectants to safeguard drug and biologic manufacturing. Biopharmaceutical growth and GMP compliance drive investment in automated sterilization and antimicrobial coatings.

Regional Insights

The Northeast region dominates the United States infection control market due to a high concentration of hospitals, research institutes, and pharmaceutical companies in states like New York, Massachusetts, and Pennsylvania. Stringent infection prevention regulations and an aging population with elevated healthcare spending contribute to this dominance. Urban density and frequent travel amplify infection risks, leading to greater investments in preventive healthcare and hospital-acquired infection control.

Ask an Analyst: https://www.imarcgroup.com/request?type=report&id=20447&flag=C

Recent Developments & News

In January 2024, ICP Medical, part of TEAM Technologies, launched a new website to enhance user experience and streamline access to infection control solutions for healthcare, industrial, and government sectors. In July 2024, BioVigil upgraded its hand hygiene monitoring badges with enhanced sensing technology and battery life, improving compliance and reducing hospital-acquired infections. In November 2024, Ondine Biomedical announced preparations for a U.S. Phase 3 trial in collaboration with HCA Healthcare to evaluate Steriwave® nasal photodisinfection to reduce hospital-associated infections and antimicrobial resistance across 14 hospitals.

Key Players

• APIC
• ICP Medical (TEAM Technologies)
• BioVigil
• Ondine Biomedical

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302

This release was published on openPR.